The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms

Leukemia

Volumn 12, Issue 9, 1998, Pages 1383-1391

  Zhang, W ^a   Ohnishi, K ^a   Shigeno, K ^a   Fujisawa, S ^a   Naito, K ^a   Nakamura, S ^a   Takeshita, K ^a   Takeshita, A ^a   Ohno, R ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Arsenic trioxide; Cell cycle arrest; Lymphoid neoplasm

Indexed keywords

ANTIMITOTIC AGENT; ARSENIC TRIOXIDE;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DAUDI CELL; HUMAN; HUMAN CELL; LYMPHOID CELL; LYMPHOMA CELL LINE; MYELOMA CELL; NONHODGKIN LYMPHOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RAJI CELL; REMISSION;

EID: 0031708772     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401112     Document Type: Article

References (27)

1. Byrd DM, Roegner ML, Griffiths JC, Lamm SH, Grumski KS, Wilson R, Lai S. Carcinogenic risks of inorganic arsenic in perspective. Int Arch Occupational Environmental Health 1996; 68: 484-494.
2. Forkner C, McNair-Scott TF. Arsenic as a therapeutic agent in chronic myeloid leukemia. JAMA 1931; 97: 305.
3. Sun HD, Ma L, Hu XL, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocyte leukemia. Chin J Intergrat Chin Western Med 1992; 12: 170-171.
4. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
5. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
6. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
7. Rivi R, Calleja E, König A, Lai L, Gambacorti-Passerini C, Scheinberg D, Gabrilove JL, Warrell RP Jr, Pandolfi PP. Organic arsenical melarsoprol shows growth suppressive activity via programmed cell death on APL and other myeloid and lymphoid leukemia derived cell lines. Blood 1996; 88 (Suppl. 1): Abstr. 68a.
8. Kitamura K, Yoshida H, Ohno R, Naoe T. Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells. Int J Hematol 1997; 65: 179-185.
9. König A, Wrazel L, Warrell RP Jr, Rivi R, Pandolfi PP, Jakubowski A, Gabrilove JL. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997; 90: 562-570.
10. Dalton WT Jr, Ahearn MJ, McCredie KB, Freireich EJ, Stass SA, Trujillo JM. HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood 1988; 71: 242-247.
11. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080-1086.
12. Kataoka T, Morishita Y, Ogura M, Morishima Y, Towatari M, Kato Y, Inoue H, Saito H. A novel human myeloid leukemia cell line, NKM-1, coexpressing granulocyte colony-stimulating factor receptors and macrophage colony-stimulating factor receptors. Cancer 1990; 50: 7703-7709.
13. Ogura M, Okumura M, Morishima T, Sugiura S, Kato Y, Hirabayashi N, Ohno R, Saito H. Establishment and characterization of a novel human B-cell lymphoma cell line (NOL-3). Jpn J Cancer Res 1986; 77 (Suppl. 1): 245.
14. Ogura M, Ueda R, Takeo T, Morishima T, Hirabayashi N, Saito H. Establishment and characterization of a novel human IgA, K myeloma cell line (NOP-1) with CD4 antigen in vitro and in vivo. Blood 1990; 74: 81a.
15. Klein F, Mahlandt BG, Lincoln RE. Growth of human lymphoid cells (Raji strain) in a five-liter fermentor. Appl Microbiol 1971; 22: 145-146.
16. Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 1968; 28: 1300-1310.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65: 55-63.
18. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991; 139: 271-279.
19. Sellins KS, Cohen JJ. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 1987; 139: 3199-3206.
20. Yoshida M, Ichikawa Y. Quantitative flow cytometric determination of cytoplasmic bcl-2 oncoprotein in peripheral blood lymphocyte subsets. Nihon Rinsho Meneki Gakkai Kaishi 1997; 20: 14-20.
21. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 3978-3983.
22. Xie Z, Zhao S, Konopleva M, Ke S, McQueen T, Reed JC, Andreeff M. Melarsoprol and arsenic trioxide increase cell death on doxorubicin-resistant human leukemia and myeloma cells by regulating expression of bcl-2 apoptosis regulatory family. Blood 1997; 90 (Suppl. 1): Abstr. 495a.
23. 3 AML. Blood 1997; 90 (Suppl 1): Abstr. 325a.
24. Isitsuka K, Suzuki S, Hanada S, Utsunomiya A, Takeuchi S, Takeshita T, Shimotakahara S, Nakahara K, Ohno N, Uozumi K, Makino T, Arima T. Arsenic acid as well as retinoic acids have therapeutic potential to adult T cell leukemia. Blood 1997; 90 (Suppl. 1): Abstr. 324a.
25. Yih LH, Huang HM, Jan KY, Lee TC. Sodium arsenite induces ATP depletion and mitochondrial damage in HeLa cells. Cell Biol Int Rep 1991; 15: 253-264.
26. EI Bahri L, Ben Romdane S. Arsenic poisoning in livestock. Vet Hum Toxicol 1991; 33: 259-264.
27. Meng Z. Effects of arsenic on DNA synthesis in human lymphocytes stimulated by phytohemagglutinin. Biol Trace Element Res 1993; 39: 73-80.